Oncoc4, Inc.

Oncoc4, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Based in Rockville, Maryland, OncoC4 is a privately held, late clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologics for the potential treatment of cancer. Its lead clinical candidate is BNT316/ONC-392, a next generation anti-CTLA-4 antibody that is designed to allow CTLA-4 to recycle and maintain its protective function against autoimmune diseases while enhancing anti-tumor activity at the same time. In addition, OncoC4 has a pipeline of potentially first-in-class preclinical product candidates focusing on the CD24-Siglecs cancer immune evasion pathway.

Company Details

Employees
63
Founded
-
Address
9640 Medical Center Dr, Rockville,maryland 20850,united States
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Keywords
Technician jobs.
HQ
Rockville, Maryland
Looking for a particular Oncoc4, Inc. employee's phone or email?

Oncoc4, Inc. Questions

News

OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates - PR Newswire

OncoC4 Closes Nearly $50 Million in Series B Financing to Advance Multiple Pipeline Candidates PR Newswire

OncoC4 Strengthens Leadership Team with Appointment of Shiniu Wei as Chief Financial Officer - GlobeNewswire

OncoC4 Strengthens Leadership Team with Appointment of Shiniu Wei as Chief Financial Officer GlobeNewswire

OncoC4 to Present Global Pivotal Phase 3 Trial Design for Next-Generation CTLA-4 Antibody Gotistobart Monotherapy Being Co-Developed with BioNTech in NSCLC at the IASLC 2025 World Conference on Lung Cancer - Yahoo Finance

OncoC4 to Present Global Pivotal Phase 3 Trial Design for Next-Generation CTLA-4 Antibody Gotistobart Monotherapy Being Co-Developed with BioNTech in NSCLC at the IASLC 2025 World Conference on Lung Cancer Yahoo Finance

OncoC4 Doses First Patient with Potential Best-in-Class PD-1/VEGF Bispecific Antibody AI-081 in Phase 2 Portion of BIPAVE-001 Trial for Advanced Solid Tumors in US - GlobeNewswire

OncoC4 Doses First Patient with Potential Best-in-Class PD-1/VEGF Bispecific Antibody AI-081 in Phase 2 Portion of BIPAVE-001 Trial for Advanced Solid Tumors in US GlobeNewswire

OncoC4 Announces New Preclinical Data Highlighting ONC-841, - GlobeNewswire

OncoC4 Announces New Preclinical Data Highlighting ONC-841, GlobeNewswire

OncoC4 founders take own science under their wing in new biotech merger - Fierce Biotech

OncoC4 founders take own science under their wing in new biotech merger Fierce Biotech

Study launches of BNT316/ONC-392 plus radioligand therapy in mCRPC - Urology Times

Study launches of BNT316/ONC-392 plus radioligand therapy in mCRPC Urology Times

OncoC4 and AcroImmune Merge - citybiz

OncoC4 and AcroImmune Merge citybiz

OncoC4 Selected to Present at the 2025 AACR Meeting's Showcase Session - GlobeNewswire

OncoC4 Selected to Present at the 2025 AACR Meeting's Showcase Session GlobeNewswire

BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC - Stock Titan

BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC Stock Titan

China's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392) - 美通社

China's NMPA Grants Breakthrough Therapy Designation for Anti-CTLA-4 Antibody Candidate Gotistobart (BNT316/ONC-392) 美通社

Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues - JCI.org

Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues JCI.org

OncoC4 Announces First Patient with Advanced Prostate Cancer Dosed in Phase 1/2 Trial of BioNTech-partnered BNT316/ONC-392 Program - Yahoo Finance

OncoC4 Announces First Patient with Advanced Prostate Cancer Dosed in Phase 1/2 Trial of BioNTech-partnered BNT316/ONC-392 Program Yahoo Finance

OncoC4 Announces FDA Clearance of IND Application for - GlobeNewswire

OncoC4 Announces FDA Clearance of IND Application for GlobeNewswire

OncoC4 Announces Fast Track Designation Granted by the U.S. - GlobeNewswire

OncoC4 Announces Fast Track Designation Granted by the U.S. GlobeNewswire

Top Oncoc4, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant